Era una notte buia e tempestosa. Ad un tratto echeggiò uno sparo! Una porta
Post by FF68Ehi marionetta , lo hai capito che esistono malati di Aids
che risultano negativi al test?
buffoncello, mi dai la definizione di AIDS e sieropositività, così capiamo
se sai di cosa parli?
Post by FF68Certo , tipo trovare la connessione tra Aids e HIV su una
rivista scientifica , cosa che Mullis chiede da anni
deve essere un analfabeta, visto che qui sotto leggi una piccolissima
bibliografia di articoli che tutti, in misura diverse, esplorano : i
meccanismi di azione e di replicazione del virus HIV-1, i suoi legami con
la distruzione dei linfociti CD4, e l'effetto delle HAART sul virus, sulla
conta dei CD4 e sulle infezioni derivanti dall'AIDS.
Ed è solo un piccolissimo assaggio. In più di 5 minuti avrei fatto senza
dubbio di meglio.
Correlations among measures of quality in HIV care in the United States:
cross sectional study
Wilson et al.
BMJ 2007;335:1085-1085.
Reproduction and fertility in human immunodeficiency virus type-1 infection
van Leeuwen et al.
Hum Reprod Update 2007;13:197-206.
Micronutrients in HIV-positive persons receiving highly active
antiretroviral therapy
Drain et al.
Am. J. Clin. Nutr. 2007;85:333-345.
The Impact of Managed Care on Access to Highly Active Antiretroviral
Therapy and on Outcomes among Medicaid Beneficiaries with AIDS
Zingmond et al.
Med Care Res Rev 2007;64:66-82.
AIDS-related non-Hodgkin's lymphoma in the first decade of highly active
antiretroviral therapy
Palmieri et al.
QJM 2006;99:811-826.
Rapid Viral Decay in Simian Immunodeficiency Virus-Infected Macaques
Receiving Quadruple Antiretroviral Therapy
Brandin et al.
J. Virol. 2006;80:9861-9864.
Functional Correlation between a Novel Amino Acid Insertion at Codon 19 in
the Protease of Human Immunodeficiency Virus Type 1 and Polymorphism in the
p1/p6 Gag Cleavage Site in Drug Resistance and Replication Fitness.
Brann et al.
J. Virol. 2006;80:6136-6145.
The management of meningeal lymphoma in patients with HIV in the era of
HAART: intrathecal depot cytarabine is effective and safe
Mazhar et al.
Blood 2006;107:3412-3414.
Quality of HIV Care Provided by Nurse Practitioners, Physician Assistants,
and Physicians
Wilson et al.
ANN INTERN MED 2005;143:729-736.
Patients' readiness to start highly active antiretroviral treatment for HIV
Gebrekristos et al.
BMJ 2005;331:772-775.
High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full
Replication Assay That Includes HIV-1 Vif as an Antiviral Target
Cao et al.
Antimicrob. Agents Chemother. 2005;49:3833-3841.
Marginal Structural Models for Estimating the Effect of Highly Active
Antiretroviral Therapy Initiation on CD4 Cell Count
Cole et al.
Am J Epidemiol 2005;162:471-478.
Assessment of the efficacy of total lymphocyte counts as predictors of AIDS
defining infections in HIV-1 infected people
Stebbing et al.
Postgrad. Med. J. 2005;81:586-588.
Insertions in the Human Immunodeficiency Virus Type 1 Protease and Reverse
Transcriptase Genes: Clinical Impact and Molecular Mechanisms
Winters and Merigan
Antimicrob. Agents Chemother. 2005;49:2575-2582.
Adherence to trizivir and tenofovir as a simplified salvage regimen is
associated with suppression of viraemia and a decreased cholesterol
Latham et al.
J Antimicrob Chemother 2005;56:186-189.
Antiretroviral Therapy in Resource-Poor Countries: Illusions and Realities
Desvarieux et al.
Am. J. Public Health 2005;95:1117-1122.
Physician Specialization and the Quality of Care for Human Immunodeficiency
Virus Infection
Landon et al.
Arch Intern Med 2005;165:1133-1139.
Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients
Receiving HAART
Nettles et al.
JAMA 2005;293:817-829.
Sexual risk behaviour of Canadian participants in the first efficacy trial
of a preventive HIV-1 vaccine
Lampinen et al.
CMAJ 2005;172:479-483.
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors
Ernest et al.
J. Pharmacol. Exp. Ther. 2005;312:583-591.
Differential Maintenance of the M184V Substitution in the Reverse
Transcriptase of Human Immunodeficiency Virus Type 1 by Various Nucleoside
Antiretroviral Agents in Tissue Culture
Petrella et al.
Antimicrob. Agents Chemother. 2004;48:4189-4194.
Amino Acid Insertions near Gag Cleavage Sites Restore the Otherwise
Compromised Replication of Human Immunodeficiency Virus Type 1 Variants
Resistant to Protease Inhibitors
Tamiya et al.
J. Virol. 2004;78:12030-12040.
Antiretroviral Therapy in HIV Infection: Are Neurologically Active Drugs
Important?
Cysique et al.
Arch Neurol 2004;61:1699-1704.
Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy
Anderson
The Annals of Pharmacotherapy 2004;38:1924-1934.
Resolution of lymphocytic interstitial pneumonitis in an HIV infected adult
after treatment with HAART
Innes et al.
Sex. Transm. Infect. 2004;80:417-418.
Staging for Antiretroviral Therapy Among HIV-Infected Drug Users
Wood et al.
JAMA 2004;292:1175-1177.
Imperatorin Inhibits HIV-1 Replication through an Sp1-dependent Pathway
Sancho et al.
J. Biol. Chem. 2004;279:37349-37359.
Nonadherence With Pediatric Human Immunodeficiency Virus Therapy as Medical
Neglect
Roberts et al.
Pediatrics 2004;114:e346-e353.
Immune activation set point during early HIV infection predicts subsequent
CD4+ T-cell changes independent of viral load
Deeks et al.
Blood 2004;104:942-947.
A comparison of the CD4 response to antiretroviral regimens in patients
commencing therapy with low CD4 counts
Waters et al.
J Antimicrob Chemother 2004;54:503-507.
Resistance to enfuvirtide, the first HIV fusion inhibitor
Greenberg and Cammack
J Antimicrob Chemother 2004;54:333-340.
Treatment for Adult HIV Infection: 2004 Recommendations of the
International AIDS Society-USA Panel
Yeni et al.
JAMA 2004;292:251-265.
A long-term latent reservoir for HIV-1: discovery and clinical implications
Siliciano and Siliciano
J Antimicrob Chemother 2004;54:6-9.
Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir-Boosted
Saquinavir in HIV-1-Infected Patients
Ruxrungtham et al.
J Clin Pharmacol 2004;44:793-803.
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily
Pretreated Human Immunodeficiency Virus-Infected Patients
Taburet et al.
Antimicrob. Agents Chemother. 2004;48:2091-2096.
Antiretroviral Treatment Regimens and Immune Parameters in the Prevention
of Systemic AIDS-Related Non-Hodgkin's Lymphoma
Stebbing et al.
JCO 2004;22:2177-2183.
Effects of a Quality Improvement Collaborative on the Outcome of Care of
Patients with HIV Infection: The EQHIV Study
Landon et al.
ANN INTERN MED 2004;140:887-896.
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue
in highly active antiretroviral therapy-associated lipodystrophy
Sutinen et al.
Am. J. Physiol. Endocrinol. Metab. 2004;286:E941-E949.
Intensive Care of Patients With HIV Infection: HAART Warming Improvement
but Beware of Future HAART (and Heart) Attacks
Morris and Huang
Chest 2004;125:1602-1604.
Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the
Initial Treatment of HIV-1 Infection
Gulick et al.
NEJM 2004;350:1850-1861.
HIV Survival Benefit Associated with Earlier Antiviral Therapy
Mocroft et al.
ANN INTERN MED 2004;140:578-579.
Costs associated with combination antiretroviral therapy in HIV-infected
patients
Yazdanpanah
J Antimicrob Chemother 2004;53:558-561.
HIV Drug Resistance
Clavel and Hance
NEJM 2004;350:1023-1035.
In Vitro Evaluation of Double and Triple Combinations of Antifungal Drugs
against Aspergillus fumigatus and Aspergillus terreus
Dannaoui et al.
Antimicrob. Agents Chemother. 2004;48:970-978.
Surveillance of HIV antiretroviral drug resistance in treated individuals
in England: 1998-2000
Scott et al.
J Antimicrob Chemother 2004;53:469-473.
Analysis of protease inhibitor combinations in vitro: activity of
lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and
drug-resistant isolates
Bulgheroni et al.
J Antimicrob Chemother 2004;53:464-468.
Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the
Viral Entry Inhibitor PRO 542
Jacobson et al.
Antimicrob. Agents Chemother. 2004;48:423-429.
Different Viral Rebound following Discontinuation of Antiretroviral Therapy
in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated
Mutations
de Mendoza et al.
J. Clin. Microbiol. 2004;42:862-866.
Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART
Greenspan et al.
J. Dent. Res. 2004;83:145-150.
Comparative evaluation of three computerized algorithms for prediction of
antiretroviral susceptibility from HIV type 1 genotype
Zazzi et al.
J Antimicrob Chemother 2004;53:356-360.
Clinical efficacy of antiretroviral combination therapy based on protease
inhibitors or non-nucleoside analogue reverse transcriptase inhibitors:
indirect comparison of controlled trials
Yazdanpanah et al.
BMJ 2004;328:249.
Assessment of Agreement between the AMPLICOR HIV-1 MONITOR Test Versions
1.0 and 1.5
Hill et al.
J. Clin. Microbiol. 2004;42:286-289.
Establishment of Adult Peripheral Blood Lymphocyte Subset Reference Range
for an Asian Population by Single-Platform Flow Cytometry: Influence of
Age, Sex, and Race and Comparison with Other Published Studies
Chng et al.
CVI 2004;11:168-173.
Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on
triple therapy including either zidovudine or stavudine
Bocket et al.
J Antimicrob Chemother 2004;53:89-94.
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1
Infection
Robbins et al.
NEJM 2003;349:2293-2303.
Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug
Regimens as Initial Therapy for HIV-1 Infection
Shafer et al.
NEJM 2003;349:2304-2315.
Infection with Multiple Human Immunodeficiency Virus Type 1 Variants Is
Associated with Faster Disease Progression
Sagar et al.
J. Virol. 2003;77:12921-12926.
Imagining and Testing New Strategies for HIV/AIDS: A Call for Papers
Smith and Glass
JAMA 2003;290:2735-2735.
Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start
Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to
0.350 x 109 cells/L
Wood et al.
ANN INTERN MED 2003;139:810-816.
Is Outpatient Care Associated with Lower Use of Inpatient and Emergency
Care? An Analysis of Persons with HIV Disease
Pezzin and Fleishman
Acad. Emerg. Med. 2003;10:1228-1238.
Meeting the immense need for HAART in resource-poor settings
Bogaards and Goudsmit
J Antimicrob Chemother 2003;52:743-746.
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection
Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort
Study
Kaufmann et al.
Arch Intern Med 2003;163:2187-2195.
Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease
Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against
Multi-PI-Resistant Human Immunodeficiency Virus In Vitro
Koh et al.
Antimicrob. Agents Chemother. 2003;47:3123-3129.
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors
in Patients with Human Immunodeficiency Virus Infection
Martinez et al.
NEJM 2003;349:1036-1046.
Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A
Randomized Trial
Squires et al.
ANN INTERN MED 2003;139:313-320.
Effect of Tenofovir on Didanosine Absorption in Patients with HIV
Fulco and Kirian
The Annals of Pharmacotherapy 2003;37:1325-1328.
Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A
Randomized, Placebo-Controlled Clinical Trial
Abrams et al.
ANN INTERN MED 2003;139:258-266.
Quality Control Trial for Human Immunodeficiency Virus Type 1 Drug
Resistance Testing Using Clinical Samples Reveals Problems with Detecting
Minority Species and Interpretation of Test Results
Korn et al.
J. Clin. Microbiol. 2003;41:3559-3565.
Is It Time To Proactively Switch Successful Antiretroviral Therapy?
Carefully Check Your SWATCH
Saag
ANN INTERN MED 2003;139:148-149.
Tuberculosis and HIV: A Partnership Against the Most Vulnerable
Cahn et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:106-123.
Human Immunodeficiency Virus Infection: A Focus on Women
Pakyz et al.
Journal of Pharmacy Practice 2003;16:170-181.
Tenofovir Disoproxil Fumarate
Grim and Romanelli
The Annals of Pharmacotherapy 2003;37:849-859.
Antiretroviral Therapy Where Resources Are Limited
Reynolds et al.
NEJM 2003;348:1806-1809.
A Novel Antiviral Intervention Results in More Accurate Assessment of Human
Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo
Markowitz et al.
J. Virol. 2003;77:5037-5038.
Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected
Persons in Different CD4+ Cell Strata
Palella et al.
ANN INTERN MED 2003;138:620-626.
When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of
Data
Lane and Neaton
ANN INTERN MED 2003;138:680-681.
Chronic HIV Infection
Jacobs and Aboulafia
ANN INTERN MED 2003;138:437-438.
Entirely Automated Quantification of Human Immunodeficiency Virus Type 1
(HIV-1) RNA in Plasma by Using the Ultrasensitive COBAS AMPLICOR HIV-1
Monitor Test and RNA Purification on the MagNA Pure LC Instrument
Holzl et al.
J. Clin. Microbiol. 2003;41:1248-1251.
Occupational Exposure to HIV in Health Care Settings
Gerberding
NEJM 2003;348:826-833.
American Thoracic Society/Centers for Disease Control and
Prevention/Infectious Diseases Society of America: Treatment of
Tuberculosis
Am. J. Respir. Crit. Care Med. 2003;167:603-662.
Treatment of advanced HIV infection
Pulido and Arribas
J Antimicrob Chemother 2003;51:225-227.
Defective mitochondrial DNA replication and NRTIs: pathophysiological
implications in AIDS cardiomyopathy
Lewis
Am. J. Physiol. Heart Circ. Physiol. 2003;284:H1-H9.
Human Immunodeficiency Virus Hematology
Volberding et al.
ASH Education Book 2003;2003:294-313.
Underpowered Clinical Trials of Antiretroviral Treatment
Arribas et al.
JAMA 2002;288:2120-2121.
New HIV Guidelines Pull Back on Antiretroviral Drugs
JWatch General 2002;2002:1-1.
The XIV International AIDS Conference: a call for action ... now
Berger
CMAJ 2002;167:483-484.
Chronic HIV Infection: Can Anyone Afford a Drug Holiday?
Kane
ANN INTERN MED 2002;137:301-304.
--
Saluti,
DIT
yet there's still something in my heart
that can find a way to make a start
to turn up the signal
wipe out the noise